Saving the Lives of People with Blood Cancer
by
After new findings from Anthony Nolan’s Patient/Donor project have been published, Jonathan from our Patient Services team looks at how new technology is helping us understand what the best possible match now looks like, and what this means for future patients. At Anthony Nolan, we use our stem cell register of over 700,000 people to…
by
Jonathan in our patient services team discusses emerging treatments for cancer, using cell therapy and new ‘super cells’. When developing a new cancer treatment, one of the most important things to consider is how well it can be tolerated by patients. Often the amount of drug that can be given is limited by the side…
by
Jonathan in the Patient Services team discusses recent research into the use of cell therapies to treat Graft versus Host Disease (GvHD), which is a common side effect of stem cell transplant. He also looks at the implications this may have for patients whose symptoms have not responded to standard treatments. Graft vs Host…
Graft vs Host Disease (GvHD) is a common complication for many patients during their recovery after a stem cell transplant. It’s caused by small differences between the new immune system and the patient’s other cells. This means the growing immune system may harm some of these cells because it sees them as ‘different’. It can…
by
A healthy gut We have known for a long time that our digestive system is home to billions of tiny microbes that help us digest our food properly. We are even encouraged to look after them by drinking “pro-biotic” products that we are told will aid our digestion. But recent research has shown that bacteria…
by
By David Marks, Medical Director of IMPACT. Stem cell transplants give a second chance of life to 4,400[i] people a year in the UK, but sadly, fewer than half of patients will reach the milestone of five-year survival. Much-needed improvements in patient outcomes can only be achieved through pioneering research. Clinical trials are crucial…
